Skip to main content

ABCL

Stock

ABCL

Stock
Health Care
Biotechnology

Performance overview

ABCL Price
Price Chart

Forward-looking statistics

Beta
0.85
Risk
64.01%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Company info

SectorHealth Care
IndustryBiotechnology
Employees522
Market cap$1.1B

Fundamentals

Enterprise value$486.4M
Revenue$23.1M
Revenue per employee—
Profit margin100.00%
Debt to equity6.63

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.56
Dividend per share—
Revenue per share$0.08
Avg trading volume (30 day)$25M
Avg trading volume (10 day)$28M
Put-call ratio—

Macro factor sensitivity

Growth+1.1
Credit+4.1
Liquidity-3.8
Inflation-0.4
Commodities+0.4
Interest Rates-0.6

Valuation

Dividend yield0.00%
PEG Ratio-5.76
Price to sales49.07
P/E Ratio-5.76
Enterprise Value to Revenue21.04
Price to book1.11

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why

ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (June 3, 2025)
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga (August 20, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free